- Patients
- Clinical Research
- Clinical trials
- DYNASTY-Breast-02
Breast Cancer
DYNASTY-Breast-02
A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)
Trial overview
Medical Oncology
Breast cancer
III
St Andrew's Precinct (Oncology)
Level 1, 337 South Terrace, Adelaide, SA, 5000, Australia
(08) 8228 6700 infooncologysa@genesiscare.comMedical Oncologist
A/Prof Nick Murray
BM MS MA DPhil FRCP(Lon) FRACP
St Andrew's Precinct (Oncology)
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.